| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Assessment of older people: self-maintaining and instrumental activities of daily living.
|
Gerontologist
|
1969
|
45.63
|
|
2
|
Frailty in older adults: evidence for a phenotype.
|
J Gerontol A Biol Sci Med Sci
|
2001
|
42.21
|
|
3
|
STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION.
|
JAMA
|
1963
|
38.91
|
|
4
|
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
|
N Engl J Med
|
2012
|
35.24
|
|
5
|
The timed "Up & Go": a test of basic functional mobility for frail elderly persons.
|
J Am Geriatr Soc
|
1991
|
31.17
|
|
6
|
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
|
N Engl J Med
|
2011
|
26.90
|
|
7
|
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
|
N Engl J Med
|
2015
|
14.71
|
|
8
|
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
|
N Engl J Med
|
2015
|
12.74
|
|
9
|
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
|
N Engl J Med
|
2015
|
12.54
|
|
10
|
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
|
N Engl J Med
|
2015
|
11.98
|
|
11
|
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
|
EMBO J
|
1992
|
8.86
|
|
12
|
Phenotype of frailty: characterization in the women's health and aging studies.
|
J Gerontol A Biol Sci Med Sci
|
2006
|
8.00
|
|
13
|
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
|
N Engl J Med
|
2016
|
6.84
|
|
14
|
Improved overall survival in melanoma with combined dabrafenib and trametinib.
|
N Engl J Med
|
2014
|
5.65
|
|
15
|
Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.
|
Am J Epidemiol
|
2011
|
5.41
|
|
16
|
The mini-cog: a cognitive 'vital signs' measure for dementia screening in multi-lingual elderly.
|
Int J Geriatr Psychiatry
|
2000
|
4.75
|
|
17
|
The Mini-Cog as a screen for dementia: validation in a population-based sample.
|
J Am Geriatr Soc
|
2003
|
3.79
|
|
18
|
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.
|
Lancet Oncol
|
2006
|
3.75
|
|
19
|
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
|
N Engl J Med
|
2016
|
2.54
|
|
20
|
Management of cancer in the older person: a practical approach.
|
Oncologist
|
2000
|
2.50
|
|
21
|
The applications of PROs in clinical practice: what are they, do they work, and why?
|
Qual Life Res
|
2008
|
2.47
|
|
22
|
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
|
Lancet
|
2016
|
2.25
|
|
23
|
Measurement and impact of comorbidity in older cancer patients.
|
Crit Rev Oncol Hematol
|
2000
|
2.12
|
|
24
|
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
|
Ann Oncol
|
2015
|
1.90
|
|
25
|
Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans.
|
Semin Immunol
|
2012
|
1.66
|
|
26
|
Using reference data on quality of life--the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3).
|
Eur J Cancer
|
1998
|
1.60
|
|
27
|
Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1.
|
Clin Cancer Res
|
2016
|
1.60
|
|
28
|
High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population.
|
Clin Exp Immunol
|
1987
|
1.59
|
|
29
|
Human CD28 and CTLA-4 Ig superfamily genes are located on chromosome 2 at bands q33-q34.
|
Immunogenetics
|
1990
|
1.26
|
|
30
|
Multiple chronic health problems are negatively associated with health related quality of life (HRQoL) irrespective of age.
|
Qual Life Res
|
2000
|
1.15
|
|
31
|
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
|
Lancet Oncol
|
2016
|
1.14
|
|
32
|
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
|
JAMA Dermatol
|
2016
|
1.04
|
|
33
|
Reliability and validity of questions about exercise in the Canadian Study of Health and Aging.
|
Int Psychogeriatr
|
2001
|
1.01
|
|
34
|
Four Instrumental Activities of Daily Living Score as a predictor of one-year incident dementia.
|
Age Ageing
|
1993
|
0.95
|
|
35
|
[Development and contribution to the validation of a brief French version of the Yesavage Geriatric Depression Scale].
|
Encephale
|
1997
|
0.89
|
|
36
|
International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer.
|
Br J Cancer
|
2013
|
0.86
|
|
37
|
The development of immunotherapy in older adults: New treatments, new toxicities?
|
J Geriatr Oncol
|
2016
|
0.86
|
|
38
|
A systematic review of the use and validation of health-related quality of life instruments in older cancer patients.
|
Eur J Cancer
|
2008
|
0.86
|
|
39
|
Comparative performance of long and short forms of the Geriatric Depression Scale in mildly demented Chinese.
|
Int J Geriatr Psychiatry
|
2005
|
0.81
|
|
40
|
Anorexia as an independent predictor of mortality.
|
J Am Geriatr Soc
|
2005
|
0.77
|
|
41
|
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
|
Ann Oncol
|
2017
|
0.75
|
|
42
|
Immune checkpoint inhibitors and elderly people: A review.
|
Eur J Cancer
|
2017
|
0.75
|
|
43
|
[Innovative therapies for metastatic melanoma in elderly patients].
|
Ann Dermatol Venereol
|
2015
|
0.75
|